EGFR and non-small cell lung carcinoma: If PDL1 is negative and there is decrease in TMB, little benefit from ICIs, in EGFR + NSCLC, ICIs has limited activity, ICI + TKI in EFGR/ALK-positive raised concern, in EGFR and ALK + NSCLC, atezolizumab + platinum - base chemotherapy + bevacizumab is a potential treatment